The FDA is proposing new rules that would permanently prevent specialty pharmacies from making their own versions of popular GLP-1 drugs like semaglutide and tirzepatide.
Posts published in “GLP-1”
A new study suggests GLP-1 medications may reduce levels of amyloid-beta and tau proteins linked to Alzheimer's disease. This potential brain-protective benefit could change how we think about these drugs beyond their weight loss effects.
Bone broth provides lean protein, essential electrolytes, and hydration that can help GLP-1 users manage side effects and preserve muscle mass during weight loss. This nutrient-rich food fits well into the dietary needs of people taking these medications.
Orforglipron, a new pill-form GLP-1 drug, performed better than oral semaglutide in clinical trials for blood sugar control and weight loss. However, the medication may cause more side effects than current options, and it's easier to manufacture and store than existing treatments.
A comprehensive review of research studies suggests that GLP-1 medications like Ozempic and Wegovy might reduce the protein buildup associated with Alzheimer's disease.
Health Canada has approved the first generic version of Ozempic, made by Dr Reddy's Laboratories, which could provide a lower-cost alternative to the popular diabetes medication. This approval marks increased competition in the growing GLP-1 drug market.
New studies suggest tirzepatide, a popular weight loss medication, may help prevent heart disease in people at high risk. This adds to the growing list of health benefits beyond weight loss for GLP-1 drugs like tirzepatide.
Farmers are shifting to growing more peas and lentils as GLP-1 weight loss medications and social media protein trends drive up demand for plant-based proteins. This agricultural shift reflects how these medications are changing food markets beyond just helping people lose weight.